Successful administration of aggressive chemotherapy concomitant to tuberculostatic and highly active antiretroviral therapy in a patient with AIDS-related Burkitt's lymphoma

HIV Medicine

Volumn 6, Issue 1, 2005, Pages 51-53

  Lehmann, Clara ^a,c   Wyen, C ^a   Hoffmann, C ^b   Fatkenheuer G ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

AIDS associated non Hodgkin's lymphoma; HAART; HIV; Tuberculosis

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EFAVIRENZ; ETHAMBUTOL; IFOSFAMIDE; IMMUNOGLOBULIN; ISONIAZID; LACTATE DEHYDROGENASE; LAMIVUDINE; METHOTREXATE; PREDNISONE; PYRAZINAMIDE; RIFAMPICIN; TENOFOVIR; TUBERCULOSTATIC AGENT; VINCRISTINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BACTERIUM CULTURE; BRONCHOSCOPY; BURKITT LYMPHOMA; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONVALESCENCE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOCHEMISTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; MALE; MUCOSA INFLAMMATION; MYCOBACTERIUM TUBERCULOSIS; PLEURA BIOPSY; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INHIBITION; VOMITING;

EID: 13944268832     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00262.x     Document Type: Article

References (13)

1. Antinori A, Cingolani A, Alba L et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15: 1483-1491.
2. Little RF, Pittaluga S, Grant N et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101: 4653-4659.
3. Sparano JA, Lee S, Chen MG et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol 2004; 22: 1491-1500.
4. Hoelzer D, Ludwig WD, Thiel E et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87: 495-508.
5. Straus DJ. Treatment of Burkitt's lymphoma in HIV-positive patients. Biomed Pharmacother 1996; 50: 447-450.
6. Conti S, Masocco M, Pezzotti P et al. Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses. J Acquir Immune Defic Syndr 2000; 25: 451-458.
7. Spina M, Tirelli U, Zagonel V et al. Burkitt's lymphoma in adults with and without human immunodeficiency virus infection: a single-institution clinicopathologic study of 75 patients. Cancer 1998; 82: 766-774.
8. Besson C, Goubar A, Gabarre J et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98: 2339-2344.
9. Ratner L, Lee J, Tang S et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19 2171-2178.
10. Wang ES, Straus DJ, Teruya-Feldstein J et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunod eficiency virus-associated Burkitt lymphoma. Cancer 2003; 98: 1196-1205.
11. Cortes J, Thomas D, Rios A et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94: 1492-1499.
12. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41: 681-690.
13. Hoffmann C, Wolf E, Fatheuheur G et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003; 17: 1521-1529.